Vinati Organics Ltd (VINATIORGA) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Vinati Organics is a specialty chemicals company that is the world's largest manufacturer of ATBS and IBB, with roughly 65% estimated global market share and about 56% of revenue from exports. The Q2 print will speak to whether EBITDA margins hold near management's 26-27% long-term guidance after Q1 FY27's margin compression, and whether the antioxidants business gets relief from the pending anti-dumping duty case against Chinese undercutting.

Vinati Organics Ltd Q2 Results Date and Time

The board will meet on Friday, October 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the limited review report. The trading window for designated persons was closed from October 1, 2026 until 48 hours after the meeting concludes.

No dividend decision is on the October 30 board agenda. The FY26 final dividend of Rs. 8.50 per share (850% on a Rs. 1 face value) was already approved at the 37th AGM held on September 23, 2026, with a record date of September 16, 2026.

Key Things To Watch

Performance vs guidance tracking: Management's May 27, 2026 guidance stack remains formally intact; here is what to check against each item.

• EBITDA margin — 26-27% open-ended guidance — Q1 FY27 PAT margin already 17.71% vs FY26's 21.89%; ask for the Q2 EBITDA margin bridge
• ATBS volume growth — 15-20% in FY27 — H1 volume tracking and status of the 40,000 MT to 50,000 MT capacity balance commissioning
• Company volume growth — approximately 15% in FY27 — aggregate volume disclosure
• VOPL revenue — Rs. 100-120 Cr in FY27 — contribution start timing: Q2 per call summary vs Q3 per transcript; seek clarity
• Capex — Rs. 200-250 Cr in FY27 — deployment progress
• Antioxidants + butyl phenols revenue — Rs. 800-900 Cr within the next two years — ADD decision status on a 6-9 month timeline from around May 2026
• IB / HP-MTBE — double-digit growth in FY27 — recovery from FY26 IBB volumes falling 20%
• New niche products — commissioning in H2 FY27 with revenue contributions beginning FY28 — commissioning updates

Margin trajectory vs the 26-27% EBITDA guide: Margin is the central issue for this print.

• Q1 FY27 standalone PAT grew 9.56% YoY on 28.67% revenue growth but fell 10.15% QoQ — probe whether EBITDA margin is trending toward the 26-27% normalisation the rating agency expects from FY26's 30.67% PBILDT margin
• Drivers to quantify on the call: raw materials, product mix, expansion costs, the Rs. 20.14 Cr Q1 inventory build and the Rs. 14.70 Cr VOPL pre-revenue drag

Antioxidants and anti-dumping duty status: Chinese competition remains the dominant risk overhang.

• Whether Chinese undercutting has eased and the reapplied ADD case (DGTR investigation initiated June 24, 2026, still ongoing as of October 1, 2026) has progressed toward a preliminary-findings timeline
• Reconcile the AO plant's ~5% FY26 growth with the 15% AO revenue growth reported for FY26

VOPL ramp and contribution timing: The wholly owned subsidiary is the newest revenue lever.

• VOPL turnover more than doubled in FY26 to Rs. 21.94 Cr from Rs. 10.55 Cr in FY25; check whether the Rs. 100-120 Cr FY27 target timeline survives the ~6-month process reengineering delay
• Clarify whether revenue contribution starts in Q2 FY27 (call summary) or Q3 FY27 onwards (transcript), and whether the Rs. 14.70 Cr Q1 subsidiary drag widens

Balance sheet and capex cadence: The debt-free policy entered the quarter intact.

• Debt-free status with a Rs. 190 Cr treasury and borrowings down to Rs. 26.71 Cr in FY26 from Rs. 76.41 Cr in FY25; CARE AA+; Stable / CARE A1+ reaffirmed on October 8, 2026
• Probe the Rs. 250-300 Cr annual capex cadence over the next 3-5 years against the Rs. 200-250 Cr FY27 budget and FY26 capex of Rs. 269.56 Cr